# Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

> **NCT00793650** · PHASE1,PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 39 (actual)

## Conditions studied

- Cancer
- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Melphalan
- **PROCEDURE:** Autologous PBSC Transplant

## Key facts

- **NCT ID:** NCT00793650
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2009-10
- **Final completion:** 2011-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793650, "Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00793650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*